Compare WILC & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WILC | SGHT |
|---|---|---|
| Founded | 1994 | 2011 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Food Distributors | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 416.3M | 395.5M |
| IPO Year | 1997 | 2021 |
| Metric | WILC | SGHT |
|---|---|---|
| Price | $28.38 | $6.12 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $8.23 |
| AVG Volume (30 Days) | 14.8K | ★ 321.9K |
| Earning Date | 03-10-2026 | 03-04-2026 |
| Dividend Yield | ★ 2.91% | N/A |
| EPS Growth | ★ 64.86 | N/A |
| EPS | ★ 2.05 | N/A |
| Revenue | ★ $180,746,882.00 | $76,052,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.07 |
| P/E Ratio | $14.06 | ★ N/A |
| Revenue Growth | ★ 4.22 | N/A |
| 52 Week Low | $12.54 | $2.03 |
| 52 Week High | $30.89 | $9.24 |
| Indicator | WILC | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 48.44 | 32.01 |
| Support Level | $29.04 | $5.94 |
| Resistance Level | $29.63 | $6.72 |
| Average True Range (ATR) | 0.85 | 0.43 |
| MACD | -0.23 | -0.13 |
| Stochastic Oscillator | 61.43 | 6.54 |
G. Willi-Food International Ltd is a company engaged in high-quality, great-tasting kosher food products. The Company is engaged, directly and through subsidiaries, with one segment Import-export, marketing, and distribution of food products. The principal product line includes Canned Vegetables and Pickles, Canned Fish, Canned Fruit, Edible Oils, Dairy and Dairy Substitute Products, Dried Fruit, Nuts and Beans, and Other Products. Its brands include Willi-Food, Euro European Dairies, Donna Rozza, Manchow, Gold Frost, Tifeeret, The Chef Dish, Art Coffe, Mr. Chang, Muchi, Euro Butter, Euro Spread, Euro Cheese, Euro Cream, Euro Dessert, Euro Veg, Ha-Bulgaria, Gelato, and Emma.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.